Is Amdocs (DOX) Now An Opportunity After Recent Share Price Weakness?

• If you are wondering whether Amdocs at around US$73 is a bargain or a value trap, you are asking the right question for this stock right now.
• The share price is at US$73.06, with returns of a 10.7% decline over the last week, a 9.8% decline over the last month, an 8.9% decline year to date, a 15.0% decline over 1 year, and a 4.2% gain over 5 years. These moves could change how investors view both risk and opportunity.
• Recent coverage of Amdocs has focused on its role as a software and services provider to telecom and media companies, and how that positioning fits into long term digital transformation trends. This context is important when thinking about why some investors may be reassessing what they are willing to pay for the stock today.
• On our checks, Amdocs scores 6 out of 6 for being undervalued across key metrics. Next we will look at how different valuation approaches line up on that view before finishing with a broader way to think about what the current price really offers.

Find out why Amdocs's -15.0% return over the last year is lagging behind its peers.

Approach 1: Amdocs Discounted Cash Flow (DCF) Analysis

A discounted cash flow, or DCF, model takes estimates of the cash a business could generate in the future and discounts those cash flows back to today to arrive at an estimate of what the entire company might be worth now.

For Amdocs, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $758.0 million, and analysts and extrapolated estimates put projected free cash flow at $956.5 million in 2030. Simply Wall St provides a detailed path between those points, with annual projections in the hundreds of millions of dollars, all expressed in $ and discounted back to today using the DCF framework.

On this basis, the estimated intrinsic value comes out at about $132.92 per share, compared with the current share price of around $73.06. That implies the stock is trading at roughly a 45.0% discount to this DCF estimate, which is a substantial gap for a cash flow driven model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Amdocs is undervalued by 45.0%. Track this in your watchlist or portfolio, or discover 868 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Amdocs.

Approach 2: Amdocs Price vs Earnings

For a profitable company like Amdocs, the P/E ratio is a useful way to connect what you pay for each share with the earnings that support it. In simple terms, a “normal” or “fair” P/E tends to be higher when investors expect stronger earnings growth and are comfortable with the company’s risk profile, and lower when growth expectations are more modest or risks are higher.

Amdocs currently trades on a P/E of 13.8x. That sits below both the IT industry average P/E of 26.1x and a peer group average of 14.8x, which indicates that the market is pricing Amdocs at a discount to many similar businesses. Simply Wall St’s “Fair Ratio” for Amdocs is 24.5x, which is its proprietary view of what the P/E might be given factors such as earnings growth, industry, profit margin, market cap and identified risks.

The Fair Ratio adds context that simple peer or industry comparisons cannot, because it is tailored to Amdocs rather than applying a broad sector multiple. Comparing the current P/E of 13.8x with the Fair Ratio of 24.5x suggests the shares are trading meaningfully below that tailored benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1426 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Amdocs Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. Narratives let you attach a clear story to your numbers, including your view of fair value and your expectations for Amdocs’ future revenue, earnings and margins.

A Narrative is simply your own written perspective on the company that connects what Amdocs does, how you think its business will develop, and what that means for a financial forecast and a fair value per share. On Simply Wall St, Narratives live in the Community page, where millions of investors can create and compare these story plus forecast views using the same framework. Each Narrative translates your assumptions into a Fair Value that you can line up against the current market price, which can help you consider whether you see Amdocs as closer to a potential buy, hold, or sell. Narratives update automatically when new information such as earnings or news is added, so your fair value view stays aligned with the latest data. For example, one Amdocs Narrative on the Community page might reflect a much higher fair value than another that takes a more cautious stance on future growth and profitability.

Do you think there's more to the story for Amdocs? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com